Drugs / HST-1011
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05662397 | Mar 2023 → Dec 2025 overdue | cancer | HotSpot Therapeutics, Inc | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HST-1011 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05662397 ↗ |
| Action | Inhibit | “HST-1011, a CBL-B inhibitor” NCT05662397 ↗ |
| Route | Oral | “HST-1011 given orally” NCT05662397 ↗ |